We believe patients
We are deeply committed to making game-changing cell therapies broadly accessible to patients with autoimmune disease and cancer
Artiva Biotherapeutics: Unlocking NK Cell Therapy for Cancer and Autoimmune Disease
The past decade has seen meaningful advances in cell therapy, with dramatic rates of clinical response in hematological malignancies and autoimmune disease. However, these therapies have been accompanied by severe and potentially life-threatening toxicities, and patient access is limited by complex, time-consuming, and costly patient-specific manufacturing. Cell therapy today is for the few, but we can do more.
Artiva Biotherapeutics is an immunotherapy company with the ability to produce off-the-shelf, allogeneic NK cell therapies at a massive scale. Our mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Our lead program, AlloNK®, is an allogeneic, non-genetically modified NK cell therapy candidate designed to enhance the activity of monoclonal antibodies or NK cell engagers. AlloNK is currently in clinical trials in combination with rituximab for treatment of systemic lupus erythematosus (SLE) in patients with active lupus nephritis and for treatment of Non-Hodgkin Lymphoma, as well as in combination with Affimed’s innate cell engager AFM13 for the treatment of patients with relapsed/refractory CD30-positive lymphomas.